Literature DB >> 22023900

Update on glucocorticoid-induced osteoporosis.

Michael Maricic1.   

Abstract

Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and fractures are the most frequent adverse effects of this medication. Glucocorticoids have several direct and indirect adverse effects on bone, primarily through reduction in osteoblasts and osteocyte activity, and life span. Recent advances in the pathophysiology and prevention of this complication of therapy provide hope for its amelioration in patients being treated with glucocorticoids. Several effective pharmacologic agents are now available, and guidelines for the prevention and treatment of GIOP have been published. Despite these advances, many patients still do not receive proper prevention or therapy.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22023900     DOI： 10.1016/j.rdc.2011.07.003

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  16 in total

Review 1.  Osteoporosis after renal transplantation.

Authors:  Evangelia Dounousi; Konstantinos Leivaditis; Theodoros Eleftheriadis; Vassilios Liakopoulos
Journal:  Int Urol Nephrol       Date:  2014-11-11       Impact factor: 2.370

2.  Corticosteroid use in neuro-oncology: an update.

Authors:  Patrick Roth; Caroline Happold; Michael Weller
Journal:  Neurooncol Pract       Date:  2014-10-09

3.  The Look AHEAD Trial: bone loss at 4-year follow-up in type 2 diabetes.

Authors:  Edward W Lipkin; Ann V Schwartz; Andrea M Anderson; Cralen Davis; Karen C Johnson; Edward W Gregg; George A Bray; Robert Berkowitz; Anne L Peters; Amelia Hodges; Cora Lewis; Steven E Kahn
Journal:  Diabetes Care       Date:  2014-07-21       Impact factor: 19.112

Review 4.  Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Authors:  Yujuan Zhang; Diana Milojevic
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

5.  Dexamethasone-loaded hollow hydroxyapatite microsphere promotes odontogenic differentiation of human dental pulp cells in vitro.

Authors:  Menglin Zhang; Shilei Ni; Xue Zhang; Jinjin Lu; Siyu Gao; Yalan Yang; Zhe Wang; Hongchen Sun; Yi Li
Journal:  Odontology       Date:  2019-10-09       Impact factor: 2.634

6.  Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale.

Authors:  Sara Pasqualetti; Terenzio Congiu; Giuseppe Banfi; Massimo Mariotti
Journal:  Int J Exp Pathol       Date:  2015-01-21       Impact factor: 1.925

Review 7.  Sex and Management of Rheumatoid Arthritis.

Authors:  Ennio Giulio Favalli; Martina Biggioggero; Chiara Crotti; Andrea Becciolini; Maria Gabriella Raimondo; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

Review 8.  Rheumatoid arthritis in the elderly in the era of tight control.

Authors:  Martin Soubrier; Zuzana Tatar; Marion Couderc; Sylvain Mathieu; Jean-Jacques Dubost
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

Review 9.  Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.

Authors:  B F Ricciardi; J Paul; A Kim; L A Russell; J M Lane
Journal:  Osteoporos Int       Date:  2012-09-07       Impact factor: 4.507

10.  Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts.

Authors:  Kaichi Kaneko; Natsuko Kusunoki; Tomoko Hasunuma; Shinichi Kawai
Journal:  J Clin Endocrinol Metab       Date:  2012-07-12       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.